Tempest Therapeutics Correlations
| TPST Stock | USD 0.92 0.01 1.10% |
The current 90-days correlation between Tempest Therapeutics and Lumos Pharma is 0.03 (i.e., Significant diversification). The correlation of Tempest Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Tempest Therapeutics Correlation With Market
Average diversification
The correlation between Tempest Therapeutics and DJI is 0.17 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Tempest Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Tempest |
Moving together with Tempest Stock
| 0.67 | A | Agilent Technologies | PairCorr |
| 0.88 | ME | 23Andme Holding | PairCorr |
| 0.66 | VALN | Valneva SE ADR | PairCorr |
| 0.62 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.86 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.71 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.79 | IPSC | Century Therapeutics | PairCorr |
| 0.83 | MTEM | Molecular Templates | PairCorr |
| 0.81 | NKTX | Nkarta Inc | PairCorr |
| 0.81 | AGL | agilon health Buyout Trend | PairCorr |
| 0.7 | CYRX | Cryoport | PairCorr |
| 0.76 | SHG | Shinhan Financial | PairCorr |
| 0.78 | EC | Ecopetrol SA ADR | PairCorr |
| 0.76 | HYMTF | Hyundai Motor | PairCorr |
| 0.76 | TLK | Telkom Indonesia Tbk | PairCorr |
Moving against Tempest Stock
| 0.53 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.5 | KZR | Kezar Life Sciences | PairCorr |
| 0.4 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.82 | BAC | Bank of America Aggressive Push | PairCorr |
| 0.81 | JPM | JPMorgan Chase Fiscal Year End 10th of January 2025 | PairCorr |
| 0.73 | CVX | Chevron Corp Fiscal Year End 7th of February 2025 | PairCorr |
| 0.72 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
| 0.68 | HPQ | HP Inc | PairCorr |
| 0.64 | T | ATT Inc Sell-off Trend | PairCorr |
| 0.6 | KB | KB Financial Group | PairCorr |
| 0.58 | INTC | Intel Fiscal Year End 23rd of January 2025 | PairCorr |
| 0.47 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.44 | HD | Home Depot | PairCorr |
| 0.36 | VFS | VinFast Auto Earnings Call Today | PairCorr |
Related Correlations Analysis
| -0.01 | 0.87 | -0.52 | 0.83 | -0.66 | ELYM | ||
| -0.01 | -0.17 | 0.1 | 0.11 | 0.01 | HCWB | ||
| 0.87 | -0.17 | -0.52 | 0.72 | -0.57 | SCPH | ||
| -0.52 | 0.1 | -0.52 | -0.42 | 0.49 | MIST | ||
| 0.83 | 0.11 | 0.72 | -0.42 | -0.6 | MCRB | ||
| -0.66 | 0.01 | -0.57 | 0.49 | -0.6 | LUMO | ||
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Tempest Stock performing well and Tempest Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Tempest Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ELYM | 3.92 | (0.95) | 0.00 | (5.36) | 0.00 | 6.21 | 34.87 | |||
| HCWB | 13.22 | 4.45 | 0.42 | (1.48) | 7.39 | 22.00 | 352.85 | |||
| SCPH | 2.68 | (0.82) | 0.00 | (0.32) | 0.00 | 4.30 | 20.70 | |||
| MIST | 1.92 | 0.21 | 0.13 | 0.25 | 1.60 | 7.19 | 18.66 | |||
| MCRB | 4.68 | 0.01 | (0.02) | 0.25 | 5.68 | 10.00 | 28.84 | |||
| LUMO | 2.77 | 0.61 | 0.15 | (3.14) | 2.60 | 6.35 | 26.13 |
Tempest Therapeutics Corporate Management
| Nicholas Maestas | VP Secretary | Profile | |
| Dr Dubensky | Pres Director | Profile | |
| Justin Trojanowski | Treasurer Controller | Profile | |
| RAC Sakai | Head Quality | Profile | |
| Samuel MD | Executive Officer | Profile | |
| Petpiboon Prasit | Acting Director | Profile | |
| Anne Moon | Project Leadership | Profile |